Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Keros Therapeutics (KROS) Income from Continuing Operations (2019 - 2025)

Keros Therapeutics filings provide 7 years of Income from Continuing Operations readings, the most recent being 23461000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 49.03% to 23461000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 87014000.0, a 146.44% increase, with the full-year FY2025 number at 87014000.0, up 146.44% from a year prior.
  • Income from Continuing Operations hit 23461000.0 in Q4 2025 for Keros Therapeutics, down from 7280000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 148451000.0 in Q1 2025 to a low of 52956000.0 in Q3 2024.
  • Median Income from Continuing Operations over the past 5 years was 28492000.0 (2022), compared with a mean of 21685150.0.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 328.21% in 2022 and later soared 444.32% in 2025.
  • Keros Therapeutics' Income from Continuing Operations stood at 6940000.0 in 2021, then plummeted by 328.21% to 29718000.0 in 2022, then crashed by 56.32% to 46455000.0 in 2023, then grew by 0.92% to 46026000.0 in 2024, then surged by 49.03% to 23461000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 23461000.0 (Q4 2025), 7280000.0 (Q3 2025), and 30696000.0 (Q2 2025) per Business Quant data.